Clinique Saint Hilaire

The department focuses on innovative strategies to improve outcomes after percutaneous coronary intervention, including studies of short-duration dual antiplatelet therapy and novel antithrombotic combinations for patients with chronic total occlusion or atrial fibrillation.

• Short-duration dual antiplatelet therapy after PCI
• PCSK9 inhibition with evolocumab in high‑risk patients
• Monotherapy with P2Y12 inhibitor following anticoagulant therapy
• Management of chronically occluded coronary arteries

Clinique Saint Hilaire collaborates with regional cardiology networks to advance these investigations and enhance patient care.

Research in the oncology unit targets locally advanced cervical cancer, evaluating the addition of atezolizumab to standard chemoradiotherapy to boost progression‑free survival and assess safety of combined modality treatment.

• PD‑L1 checkpoint inhibition combined with chemoradiotherapy
• Evaluation of progression‑free survival in cervical cancer
• Integration of novel immunotherapies into standard care
• Safety assessment of combined modality therapy

The oncology department at Clinique Saint Hilaire is part of a national cancer research consortium dedicated to improving therapeutic options.

The site also explores the metabolic dimension of cardiovascular risk, studying the effect of optimized lipid‑lowering therapy and nutritional interventions on disease progression in high‑risk populations.

• Optimized lipid‑lowering therapy in high‑risk individuals
• Impact of metabolic control on cardiovascular outcomes
• Exploration of nutritional interventions alongside cardiovascular treatment
• Assessment of metabolic biomarkers in trial participants

Clinique Saint Hilaire integrates metabolic research into its cardiovascular programs to provide a comprehensive approach to patient health.